Maze Therapeutics (MAZE) Payables (2024 - 2026)

Maze Therapeutics has reported Payables for 3 years, with the latest figure at $4.0 million in Q1 2026.

• Quarterly Payables rose 66.93% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 66.93% YoY) and the FY2025 annual result came in at $1.8 million, down 7.48% from the prior year.
• Payables improved to $4.0 million in Q1 2026 per MAZE's latest filing, from $1.8 million in the prior quarter.
• Over five years, Payables peaked at $4.0 million in Q1 2026 and troughed at $1.8 million in Q4 2025.
• A 3-year average of $2.8 million and a median of $2.7 million in 2025 frame the typical range for Payables.
• The sharpest annual moves came in 2025 and 2026: Payables decreased 7.48% in 2025, then jumped 66.93% in 2026.
• Over 3 years, Payables stood at $1.9 million in 2024, then fell by 7.48% to $1.8 million in 2025, then jumped by 123.69% to $4.0 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $4.0 million, $1.8 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.